Del Labs
This article was originally published in The Tan Sheet
Executive Summary
Former President and CEO William McMenemy has departed the company to pursue other interests, and has not retired, as reported in the Aug. 22 issue of "The Tan Sheet." Del Labs announced last month the exec was stepping down as CEO, but will continue to serve on its board of directors. McMenemy was succeeded by Chief Operating Officer William Hinkaty (1"The Tan Sheet" Aug. 22, 2005, p. 11)...
You may also be interested in...
Del Labs Announces Management Changes, New OTC Products
Del Labs former Chief Operating Officer Charles Hinkaty took the helm as president and CEO Aug. 19, succeeding retiring head William McMenemy
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.